PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16680924-7 2006 RESULTS: Montelukast-treated patients had lower residual volume (P = .05), residual volume-total lung capacity ratio (P = .04), Raw (P = .02), Sgaw (P = .03), and serum ECP levels (P = .02) at 8 weeks compared with those treated with placebo. montelukast 9-20 ribonuclease A family member 3 Homo sapiens 169-172 17165277-11 2006 Decreases in the level of eosinophil cationic protein were greater after the combined use of montelukast and antihistamine than after each agent given alone. montelukast 93-104 ribonuclease A family member 3 Homo sapiens 26-53 16948353-0 2006 Percentage of eosinophils with surface CD44 and levels of eosinophil cationic protein in the peripheral blood in children with bronchial asthma and their changes after montelukast therapy. montelukast 168-179 ribonuclease A family member 3 Homo sapiens 58-85 17163269-0 2006 Montelukast decreases plasma endothelin-1 and serum eosinophil cationic protein levels in paediatric atopic asthma. montelukast 0-11 ribonuclease A family member 3 Homo sapiens 52-79 16279568-11 2005 Compared with placebo use, montelukast treatment decreased serum and sputum levels of eosinophil cationic protein and IL-8, decreased sputum levels of myeloperoxidase, and increased serum and sputum levels of IL-10 (P < .001 for all). montelukast 27-38 ribonuclease A family member 3 Homo sapiens 86-113 15584630-4 2004 Children responding to montelukast were found to have higher blood levels of eosinophil cationic protein (S-ECP) in the pretreatment blood sample than children with no response (responders 14.88+/-2.651 microg/l versus nonresponders 6.62+/-0.948 microg/l; p<0.01). montelukast 23-34 ribonuclease A family member 3 Homo sapiens 77-104 15696076-7 2005 Greater differential response to fluticasone over montelukast was associated with higher bronchodilator use, bronchodilator response, exhaled nitric oxide levels, and eosinophil cationic protein levels and lower methacholine PC(20) and pulmonary function values. montelukast 50-61 ribonuclease A family member 3 Homo sapiens 167-194 12053590-11 2002 We found significant correlation between ECP and hyperresponsiveness after treatment with triamcinolon, montelukast. montelukast 104-115 ribonuclease A family member 3 Homo sapiens 41-44 14982509-13 2004 The in-season ECP level was significantly increased in all groups except montelukast-plus-cetirizine group. montelukast 73-84 ribonuclease A family member 3 Homo sapiens 14-17 12736396-0 2003 A randomized controlled trial on the effect of montelukast on sputum eosinophil cationic protein in children with corticosteroid-dependent asthma. montelukast 47-58 ribonuclease A family member 3 Homo sapiens 69-96 12736396-7 2003 After treatment with montelukast, ECP in sputum was significantly reduced (montelukast: median -975 microg/L [5 to 95% confidence interval: -4295 to 583 microg/L]; placebo: 561 microg/L [-1335 to 3320 microg/L]; p < 0.01) and the quality-of-life score had significantly improved (p < 0.05) compared with placebo. montelukast 21-32 ribonuclease A family member 3 Homo sapiens 34-37 12736396-7 2003 After treatment with montelukast, ECP in sputum was significantly reduced (montelukast: median -975 microg/L [5 to 95% confidence interval: -4295 to 583 microg/L]; placebo: 561 microg/L [-1335 to 3320 microg/L]; p < 0.01) and the quality-of-life score had significantly improved (p < 0.05) compared with placebo. montelukast 75-86 ribonuclease A family member 3 Homo sapiens 34-37 12736396-9 2003 In conclusion, add-on treatment with montelukast can suppress sputum ECP in children with steroid-dependent asthma, while at the same time an improvement in quality of life items occurs. montelukast 37-48 ribonuclease A family member 3 Homo sapiens 69-72 12487226-8 2002 There was a significant (P < or = 0.02) reduction of serum ECP (median reduction: montelukast 7.7 microg/L vs placebo 0.15 microg/L) and eosinophils (P < or = 0.027; median reduction: montelukast 85/microL vs placebo 0/microL). montelukast 85-96 ribonuclease A family member 3 Homo sapiens 62-65 12053590-12 2002 This study shows that triamcinolon, montelukast contribute to inhibition of allergic inflammation by decreasing eosinophil blood counts and ECP. montelukast 36-47 ribonuclease A family member 3 Homo sapiens 140-143 11929492-10 2002 We found statistically significant correlations between serum level of IL-10 and serum level of ECP after treatment with triamcinolone and montelukast. montelukast 139-150 ribonuclease A family member 3 Homo sapiens 96-99 11842294-6 2002 RESULTS: Compared to placebo, serum concentrations of IL-4, sICAM-1, and ECP and eosinophil blood counts significantly decreased after 6 weeks of treatment with montelukast. montelukast 161-172 ribonuclease A family member 3 Homo sapiens 73-76 11842294-8 2002 Montelukast resulted in within-group significant decrease in levels of serum sIL-2R (611 vs. 483 pg/mL), IL-4 (0.123 vs 0.102 pg/mL), sICAM-1 (280 vs. 244 ng/mL), and ECP (74 vs. 59 microg/mL) and in eosinophil blood counts (349 vs. 310 cells/mm(3)). montelukast 0-11 ribonuclease A family member 3 Homo sapiens 167-170 11842294-12 2002 Montelukast caused a statistically significant decrease of serum concentrations in cytokine, ICAM-1, and ECP and peripheral blood eosinophil counts over the 6-week treatment period. montelukast 0-11 ribonuclease A family member 3 Homo sapiens 105-108 25846070-10 2016 This efficacy may be related to the montelukast-induced reductions in peripheral eosinophil counts, ECP and total IgE, as well as the montelukast-dependent recovery in T helper (Th) 1/Th2 balance and LXA4/LTB4 ratios in children with bronchiolitis. montelukast 36-47 ribonuclease A family member 3 Homo sapiens 100-103 20159258-12 2010 Montelukast, likely not solely as an inhibitor of cysLT(1)R, inhibited eosinophil cationic protein release elicited by LTC(4) and LTD(4) as well as by LTE(4). montelukast 0-11 ribonuclease A family member 3 Homo sapiens 71-98